Company profile: Xbrane Biopharma
1.1 - Company Overview
Company description
- Provider of complex generic biopharmaceuticals and novel bacterial protein expression technologies, with expertise in slow-release formulations. Products include Ximluci, a biosimilar of ranibizumab (Lucentis) for eye diseases, and Spherotide, a biosimilar of Decapeptyl primarily for prostate cancer treatment.
Products and services
- Complex Generics Production & Protein Expression Technologies: Architects high-demand complex generics using slow-release formulation, leveraging specific know-how and unique bacterial protein expression technologies for protein manufacturing
- Spherotide: Produces a biosimilar of Decapeptyl for prostate cancer treatment, reflecting high-entry-barrier complexity and specific know-how in complex generics production
- Ximluci: Engineers a biosimilar of ranibizumab (Lucentis®) developed for treating eye diseases, demonstrating specialized production of complex generics
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Xbrane Biopharma
Rejuveron
HQ: Switzerland
Website
- Description: Provider of a fully integrated biotechnology platform that invests in people and ideas to develop therapies and technologies to improve healthy aging and prolong lifespan.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rejuveron company profile →
Bristol Myers Squibb
HQ: United States
Website
- Description: Provider of pharmaceuticals, engaging in the discovery, development, licensing, manufacturing, marketing, distribution and sale of therapies, including cancer immunotherapies Opdivo (nivolumab) and Yervoy (ipilimumab); anticoagulant Eliquis (apixaban); oncology treatments Revlimid (lenalidomide) and Sprycel (dasatinib); and autoimmune therapy Orencia (abatacept).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bristol Myers Squibb company profile →
Albumedix
HQ: United Kingdom
Website
- Description: Provider of albumin-based drug-enhancing technologies for superior biopharmaceuticals. Offers recombinant human albumin (Recombumin) as excipient, ancillary, and raw material to improve stability and quality; Veltis technology for half-life extension; albumin solutions for cell and gene therapy, vaccine stabilization, and medical device coating to enhance biocompatibility and delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Albumedix company profile →
Amgen
HQ: United States
Website
- Description: Provider of biotechnology-based human therapeutics, including biosimilar medicines for oncology, hematology, and chronic inflammatory diseases, and oncology therapies spanning precision oncology and targeted immunotherapy. Also offers the Amgen Biotech Experience for hands-on secondary school education and supports science education and communities through the Amgen Foundation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amgen company profile →
Sunovion
HQ: United States
Website
- Description: Provider of therapeutic products discovered, developed and commercialized for central nervous system and respiratory disorders and other illnesses. Portfolio includes Latuda for schizophrenia and bipolar depression; Aptiom for partial-onset seizures; Gemtesa/vibegron for overactive bladder; Myfembree for heavy menstrual bleeding due to uterine fibroids; Orgovyx for advanced prostate cancer; LUNESTA; and XOPENEX.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sunovion company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Xbrane Biopharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Xbrane Biopharma
2.2 - Growth funds investing in similar companies to Xbrane Biopharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Xbrane Biopharma
4.2 - Public trading comparable groups for Xbrane Biopharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →